F Cavagna1, A Pontes2, M Cavagna1, A Dzik1, N F Donadio1, R Portela1, M T Nagai1, L H Gebrim1. 1. Women's Health Reference Center, Hospital Perola Byington, Sao Paulo, Brazil. 2. Department of Gynecology and Obstetrics, Botucatu Medical School, University of the State of Sao Paulo, Botucatu, Brazil.
Abstract
Background: Fertility preservation is an important concern in breast cancer patients. In the present investigation, we set out to create a specific protocol of controlled ovarian stimulation (cos) for oocyte cryopreservation in breast cancer patients. Methods: From November 2014 to December 2016, 109 patients were studied. The patients were assigned to a specific random-start ovarian stimulation protocol for oocyte cryopreservation. The endpoints were the numbers of oocytes retrieved and of mature oocytes cryopreserved, the total number of days of ovarian stimulation, the total dose of gonadotropin administered, and the estradiol level on the day of the trigger. Results: Mean age in this cohort was 31.27 ± 4.23 years. The average duration of cos was 10.0 ± 1.39 days. The mean number of oocytes collected was 11.62 ± 7.96 and the mean number of vitrified oocytes was 9.60 ± 6.87. The mean estradiol concentration on triggering day was 706.30 ± 450.48 pg/mL, and the mean dose of gonadotropins administered was 2610.00 ± 716.51 IU. When comparing outcomes by phase of the cycle in which cos was commenced, we observed no significant differences in the numbers of oocytes collected and vitrified, the length of ovarian stimulation, and the estradiol level on trigger day. The total dose of follicle-stimulating hormone and human menopausal gonadotropin administered was statistically greater in the group starting cos in the luteal phase than in the group starting in the late follicular phase. Conclusions: Our results suggest that using a specific protocol with random-start ovarian stimulation for oocyte cryopreservation in breast cancer patients is effective and could be offered to young women undergoing oncologic treatment.
Background: Fertility preservation is an important concern in breast cancerpatients. In the present investigation, we set out to create a specific protocol of controlled ovarian stimulation (cos) for oocyte cryopreservation in breast cancerpatients. Methods: From November 2014 to December 2016, 109 patients were studied. The patients were assigned to a specific random-start ovarian stimulation protocol for oocyte cryopreservation. The endpoints were the numbers of oocytes retrieved and of mature oocytes cryopreserved, the total number of days of ovarian stimulation, the total dose of gonadotropin administered, and the estradiol level on the day of the trigger. Results: Mean age in this cohort was 31.27 ± 4.23 years. The average duration of cos was 10.0 ± 1.39 days. The mean number of oocytes collected was 11.62 ± 7.96 and the mean number of vitrified oocytes was 9.60 ± 6.87. The mean estradiol concentration on triggering day was 706.30 ± 450.48 pg/mL, and the mean dose of gonadotropins administered was 2610.00 ± 716.51 IU. When comparing outcomes by phase of the cycle in which cos was commenced, we observed no significant differences in the numbers of oocytes collected and vitrified, the length of ovarian stimulation, and the estradiol level on trigger day. The total dose of follicle-stimulating hormone and human menopausal gonadotropin administered was statistically greater in the group starting cos in the luteal phase than in the group starting in the late follicular phase. Conclusions: Our results suggest that using a specific protocol with random-start ovarian stimulation for oocyte cryopreservation in breast cancerpatients is effective and could be offered to young women undergoing oncologic treatment.
Entities:
Keywords:
Fertility preservation; breast cancer; oocyte cryopreservation; ovarian stimulation
Authors: Michael von Wolff; Ralf Dittrich; Jana Liebenthron; Frank Nawroth; Andreas N Schüring; Thomas Bruckner; Ariane Germeyer Journal: Reprod Biomed Online Date: 2015-08-11 Impact factor: 3.828
Authors: Francisca Martínez; Marta Devesa; Buenaventura Coroleu; Rosa Tur; Clara González; Montserrat Boada; Miquel Solé; Anna Veiga; Pedro N Barri Journal: Gynecol Endocrinol Date: 2013-01-24 Impact factor: 2.260
Authors: Ludmila M N Bercaire; Mario Cavagna; Nilka F Donadio; Andressa R Rocha; Rafael Portela; Vanessa R Alves; Thamara B B Santos; Felipe Cavagna; Artur Dzik; Luiz H Gebrim; Eliana A P Nahas Journal: JBRA Assist Reprod Date: 2020-07-14